バイオシミラー受託製造の世界市場

バイオシミラー受託製造の世界市場は2030年までに231億米ドルに達する見込み

2024年に98億米ドルと推定されるバイオシミラー受託製造の世界市場は、2030年には231億米ドルに達し、分析期間2024-2030年のCAGRは15.5%で成長すると予測されます。本レポートで分析したセグメントの一つである組換え非糖化タンパク質は、CAGR17.9%を記録し、分析期間終了までに158億米ドルに達すると予想されます。組換え糖質化タンパク質セグメントの成長率は、分析期間中CAGR 11.2%と推定されます。

米国市場は27億米ドル、中国はCAGR21.0％で成長すると予測される

米国のバイオシミラー受託製造市場は2024年に27億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに51億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは21.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.1%と14.0%と予測されています。欧州では、ドイツがCAGR約12.4%で成長すると予測されています。

世界のバイオシミラー受託製造市場- 主要動向と促進要因のまとめ

バイオシミラー受託製造がバイオ医薬品生産の要になりつつある理由とは？

バイオシミラー受託製造市場は、製薬会社が生物学的製剤の代替品を製造するための費用対効果が高くスケーラブルなソリューションを求めているため、急成長を遂げています。バイオシミラーとは、既に承認されている基準薬と極めて類似した生物学的製剤であり、がん、自己免疫疾患、糖尿病などの慢性疾患の治療に使用される高価な生物学的製剤に代わる、より安価な代替品を提供するものです。しかし、バイオシミラー医薬品の製造には、高度な生物学的専門知識、規制への対応、特殊な設備が必要となる複雑な製造工程が必要であるため、多くの製薬企業がCDMO（医薬品開発・製造受託機関）と提携し、製造の効率化を図っています。

ブロックバスター生物製剤の特許切れ、ヘルスケアプロバイダーによるコスト抑制策、バイオシミラー採用に対する規制当局の支援などを背景に、バイオシミラーの需要が高まっているため、高品質の受託製造サービスへのニーズが高まっています。バイオシミラーに特化したCDMOは、細胞株開発、プロセス最適化、大規模バイオプロセス、規制遵守サポートなど、エンド・ツー・エンドのソリューションを提供しています。生物製剤の手頃な価格と世界の市場拡大が重視される中、バイオシミラー受託製造は製薬会社の製造コストを削減しつつ、アクセシビリティを高める上で重要な役割を果たしています。

技術の進歩はバイオシミラー受託製造をどのように強化していますか？

シングルユースシステム、ハイスループット細胞株開発、プロセス分析技術（PAT）などのバイオプロセス技術の開発が、バイオシミラー受託製造に革命をもたらしています。最も重要なイノベーションの一つは、シングルユース・バイオリアクターの採用であり、汚染リスクと運用コストを最小限に抑えながら、柔軟でスケーラブルな生産を可能にしています。これらのバイオリアクターにより、CDMOは市場の需要に基づいて生産能力を迅速に調整することができ、効率を向上させ、製造所要時間を短縮することができます。

バイオシミラー製造におけるもう一つの大きなブレークスルーは、プロセスの最適化における人工知能（AI）と機械学習（ML）の統合です。AIを活用した予測分析により、CDMOはバイオプロセス条件を微調整し、歩留まりを向上させ、バッチ間の一貫性を確保することができます。さらに、高分解能質量分析やバイオアッセイなどのバイオシミラー特性評価技術の進歩により、バイオシミラーと参照生物製剤との比較可能性評価が向上しています。また、連続的なバイオプロセスの採用も業界に変革をもたらし、リアルタイムのモニタリングを可能にし、従来のバッチ処理に比べて製造コストを削減しています。このような技術の進歩によりバイオシミラーの製造効率が向上し続ける中、製造受託企業は、市場参入を加速させ、高品質の製造基準を維持しようとする製薬企業の戦略的パートナーとしての地位をますます高めています。

バイオシミラー受託製造の成長を牽引する市場動向は？

費用対効果の高い生物製剤に対する需要の高まりと、世界のヘルスケア市場におけるバイオシミラーの受け入れ拡大は、バイオシミラー受託製造分野の成長を後押しする大きな動向です。業界を形成する最も重要な動向のひとつは、特に腫瘍学、免疫学、内分泌学、血液学においてバイオシミラー製品のパイプラインが拡大していることです。ブロックバスター生物製剤の複数の特許が失効する中、製薬会社はバイオシミラーに代わる医薬品の開発にしのぎを削っており、信頼性と拡張性に優れた受託製造ソリューションの必要性が高まっています。

市場を形成するもう一つの主要動向は、新興市場におけるバイオシミラー採用の拡大であり、各国政府は手頃な価格の生物製剤へのアクセスを改善する政策を実施しています。中国、インド、ブラジルなどの国々では、バイオシミラー医薬品の承認が増加し、現地のバイオ医薬品インフラへの投資も増加しているため、CDMOは各地域に製造施設を設立しています。さらに、ハイブリッド製造モデル（製薬会社が細胞株開発や充填仕上げサービスなど、バイオシミラー製造の特定分野のみを外注するモデル）の台頭により、製造パートナーシップに柔軟性がもたらされています。FDAやEMAなどの規制当局も、承認経路の合理化を通じてバイオシミラー医薬品の採用を支援しており、市場の成長をさらに後押ししています。

バイオシミラー受託製造市場の将来を形作る主な成長促進要因とは？

バイオシミラー受託製造市場の成長は、規制当局の支援の増加、ヘルスケアシステムへのコスト圧力、バイオシミラーポートフォリオの拡大など、複数の要因によってもたらされます。主な成長要因の一つは、製薬企業が厳しい規制要件を遵守しながら開発・製造コストを削減する必要性です。受託製造により、バイオ医薬品企業は専門的な専門知識、最先端のインフラ、規制に関する知識を活用することができ、自社内での生物製剤製造に伴うリスクと費用を最小限に抑えることができます。

市場を形成するもう一つの重要な要因は、戦略的提携やパートナーシップの役割の増大です。大手製薬会社はCDMOと提携し、サプライチェーンの効率を最適化しながらバイオシミラーの商業化を加速させています。さらに、バイオシミラー受託製造と個別化医療や次世代生物製剤との融合が進み、イノベーションの新たな機会が生まれています。バイオシミラーの需要が増加し、製造技術が進化し続ける中、製造受託機関は、バイオ医薬品業界全体において、世界のバイオシミラーへのアクセスの拡大、高品質の製造の確保、コスト効率の推進において、さらに大きな役割を果たす態勢を整えています。

セグメント

製品タイプ（組換え非グリコシル化タンパク質、組換えグリコシル化タンパク質）、生産技術（哺乳類技術、非哺乳類技術）、用途（腫瘍学用途、血液疾患用途、成長ホルモン欠乏症用途、慢性・自己免疫疾患用途、関節リウマチ用途、その他用途）

調査対象企業の例

• AGC Biologics
• Alcami Corporation Inc.
• Almac Group
• Avid Bioservices, Inc.
• Biocon Ltd.
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Cell Therapies Pty Ltd
• Charles River Laboratories International, Inc.
• Element Materials Technology
• FujiFilm Diosynth Biotechnologies U.S.A., Inc.
• Fujifilm Kyowa Kirin Biologics Co., Ltd.
• IQVIA, Inc.
• KBI Biopharma
• Kemwell Biopharma Pvt., Ltd.
• Miltenyi Biotec GmbH
• Minaris Regenerative Medicine
• Rentschler Biopharma SE
• Samsung BioLogics Co., Ltd.
• Thermo Fisher Scientific, Inc.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Biosimilar Contract Manufacturing Market to Reach US$23.1 Billion by 2030

The global market for Biosimilar Contract Manufacturing estimated at US$9.8 Billion in the year 2024, is expected to reach US$23.1 Billion by 2030, growing at a CAGR of 15.5% over the analysis period 2024-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$15.8 Billion by the end of the analysis period. Growth in the Recombinant Glycosylated Proteins segment is estimated at 11.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 21.0% CAGR

The Biosimilar Contract Manufacturing market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.1 Billion by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 14.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Biosimilar Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Biosimilar Contract Manufacturing Becoming a Cornerstone of Biopharmaceutical Production?

The biosimilar contract manufacturing market is witnessing rapid growth as pharmaceutical companies seek cost-effective and scalable solutions to produce biologic alternatives. Biosimilars, which are biologic medicines highly similar to already approved reference drugs, offer a more affordable alternative to expensive biologics used in treating chronic diseases such as cancer, autoimmune disorders, and diabetes. However, the complex manufacturing processes involved in biosimilar production-requiring advanced biologic expertise, regulatory compliance, and specialized facilities-have led many pharmaceutical companies to partner with contract development and manufacturing organizations (CDMOs) to streamline production.

The rising demand for biosimilars, driven by patent expirations of blockbuster biologics, cost-containment measures by healthcare providers, and regulatory support for biosimilar adoption, has fueled the need for high-quality contract manufacturing services. CDMOs specializing in biosimilars provide end-to-end solutions, including cell line development, process optimization, large-scale bioprocessing, and regulatory compliance support. With the growing emphasis on biologics affordability and global market expansion, biosimilar contract manufacturing is playing a crucial role in enhancing accessibility while reducing production costs for pharmaceutical companies.

How Are Technological Advancements Enhancing Biosimilar Contract Manufacturing?

Advancements in bioprocessing technologies, including single-use systems, high-throughput cell line development, and process analytical technology (PAT), are revolutionizing biosimilar contract manufacturing. One of the most significant innovations is the adoption of single-use bioreactors, which allow flexible and scalable production while minimizing contamination risks and operational costs. These bioreactors enable CDMOs to quickly adjust production capacities based on market demand, improving efficiency and reducing manufacturing turnaround times.

Another major breakthrough in biosimilar manufacturing is the integration of artificial intelligence (AI) and machine learning (ML) in process optimization. AI-driven predictive analytics enable CDMOs to fine-tune bioprocessing conditions, enhance yield, and ensure batch-to-batch consistency. Additionally, advancements in biosimilar characterization techniques, such as high-resolution mass spectrometry and bioassays, are improving the comparability assessment between biosimilars and their reference biologics. The adoption of continuous bioprocessing is also transforming the industry, allowing for real-time monitoring and reducing production costs compared to traditional batch processing. As these technological advancements continue to enhance biosimilar manufacturing efficiency, contract manufacturers are increasingly becoming strategic partners for pharmaceutical companies looking to accelerate market entry and maintain high-quality production standards.

Which Market Trends Are Driving the Growth of Biosimilar Contract Manufacturing?

The rising demand for cost-effective biologics and the increasing acceptance of biosimilars in global healthcare markets are major trends fueling the biosimilar contract manufacturing sector. One of the most significant trends shaping the industry is the growing pipeline of biosimilar products, particularly in oncology, immunology, endocrinology, and hematology. With multiple patents on blockbuster biologics expiring, pharmaceutical companies are racing to develop biosimilar alternatives, driving the need for reliable and scalable contract manufacturing solutions.

Another key trend shaping the market is the expansion of biosimilar adoption in emerging markets, where governments are implementing policies to improve access to affordable biologics. Countries such as China, India, and Brazil are witnessing increased biosimilar approvals and investments in local biopharmaceutical infrastructure, prompting CDMOs to establish regional production facilities. Additionally, the rise of hybrid manufacturing models-where pharmaceutical companies outsource only specific segments of biosimilar production, such as cell line development or fill-finish services-is providing flexibility in manufacturing partnerships. Regulatory agencies, including the FDA and EMA, are also supporting biosimilar adoption through streamlined approval pathways, further driving market growth.

What Are the Key Growth Drivers Shaping the Future of the Biosimilar Contract Manufacturing Market?

The growth in the biosimilar contract manufacturing market is driven by multiple factors, including increasing regulatory support, cost pressures on healthcare systems, and the expansion of biosimilar portfolios. One of the primary growth drivers is the need for pharmaceutical companies to reduce development and production costs while maintaining compliance with stringent regulatory requirements. Contract manufacturing allows biopharma firms to leverage specialized expertise, state-of-the-art infrastructure, and regulatory knowledge, minimizing the risks and expenses associated with in-house biologics production.

Another crucial driver shaping the market is the increasing role of strategic collaborations and partnerships. Large pharmaceutical companies are forming alliances with CDMOs to accelerate biosimilar commercialization while optimizing supply chain efficiency. Additionally, the growing integration of biosimilar contract manufacturing with personalized medicine and next-generation biologics is opening new opportunities for innovation. As the demand for biosimilars continues to rise and manufacturing technologies evolve, contract manufacturing organizations are poised to play an even greater role in expanding global biosimilar accessibility, ensuring high-quality production, and driving cost efficiency across the biopharmaceutical industry.

SCOPE OF STUDY:

The report analyzes the Biosimilar Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins); Production Technology (Mammalian Technology, Non-Mammalian Technology); Application (Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic and Autoimmune Disorders Application, Rheumatoid Arthritis Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AGC Biologics
• Alcami Corporation Inc.
• Almac Group
• Avid Bioservices, Inc.
• Biocon Ltd.
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Cell Therapies Pty Ltd
• Charles River Laboratories International, Inc.
• Element Materials Technology
• FujiFilm Diosynth Biotechnologies U.S.A., Inc.
• Fujifilm Kyowa Kirin Biologics Co., Ltd.
• IQVIA, Inc.
• KBI Biopharma
• Kemwell Biopharma Pvt., Ltd.
• Miltenyi Biotec GmbH
• Minaris Regenerative Medicine
• Rentschler Biopharma SE
• Samsung BioLogics Co., Ltd.
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Biosimilar Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Demand for Affordable Biologics Throws the Spotlight on Biosimilar Contract Manufacturing Services
  • Patent Expiry of Blockbuster Biologics Drives Market Expansion for Biosimilar Development and Manufacturing Partnerships
  • Cost-Efficiency Pressures Among Biosimilar Developers Strengthen the Business Case for Outsourced Manufacturing Models
  • Growing Pipeline of Biosimilars Across Therapeutic Areas Expands Addressable Market Opportunity for CDMOs
  • Shift Toward Flexible and Scalable Biomanufacturing Platforms Fuels Investment in Single-Use and Modular Facilities
  • Emerging Biotech Firms and Startups Leverage CDMO Capabilities to Fast-Track Biosimilar Product Development
  • Rising Complexity in Biosimilar Analytical and Formulation Requirements Spurs Demand for Specialized Manufacturing Expertise
  • Globalization of Biosimilar Markets Drives Need for Regionally Compliant and GMP-Certified Contract Manufacturing Facilities
  • Technological Advancements in Upstream and Downstream Bioprocessing Enhance Efficiency and Scalability of CDMO Operations
  • Increased Focus on Time-to-Market Advantage Creates Opportunities for End-to-End Integrated CDMO Services
  • Expansion of Multi-Product Facilities by CDMOs Strengthens Flexibility for Multi-Client Biosimilar Production
  • Growing Demand for Fill-Finish Capabilities and Late-Stage Manufacturing Support Drives Facility Upgrades
  • Rising Investment in Emerging Markets and Low-Cost Production Hubs Opens New Avenues for Global Biosimilar Manufacturing Outsourcing
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Biosimilar Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Biosimilar Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Blood Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Blood Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Blood Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Growth Hormonal Deficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Growth Hormonal Deficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Growth Hormonal Deficiency Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Chronic & Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Chronic & Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Chronic & Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Mammalian Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Non-Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Non-Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Non-Mammalian Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• JAPAN
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• CHINA
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• EUROPE
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Biosimilar Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• FRANCE
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• GERMANY
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• INDIA
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Biosimilar Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Biosimilar Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
• AFRICA
  • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030

IV. COMPETITION